Organon & Co reported 17.56 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Celltrion 41.5 17.47 Jun/2026
Cspc Pharmaceutical 23.62 0.78 Mar/2026
Deva Holding AS 6.55 2.01 Sep/2023
Dianthus Therapeutics 3.8 1.53 Sep/2024
Divis Laboratories Ltd 58.35 1.4 Jun/2026
Gilead Sciences 17.68 4.18 Sep/2026
Glaxosmithkline 15.17 0.08 Sep/2026
Kangmei Pharma 1.11K 0 Jun/2026
Knight Therapeutics 257.34 166.24 Dec/2025
Laboratorios Farma 18.78 6.64 Dec/2023
Malin Corporation 11.81 0.72 Jun/2023
Merck 34.36 2.11 Sep/2026
Neuren Pharmaceuticals 72.14 59.86 Dec/2025
Novartis 21.54 0.18 Sep/2026
Organigram Holdings 15.55 3.54 Jun/2026
Organon & Co 17.56 3 Sep/2026
Ovoca Bio 1.83 3.29 Jun/2024
Pharma Mar 24.29 7.94 Sep/2026
Qiagen NV 16.72 2.76 Jun/2026
Sartorius 47.29 5.7 Sep/2026
Sino Biopharmaceutical 17.03 0.89 Jun/2025
Tilray 11.56 80.19 Sep/2025
Zealand Pharma A/S 3.27 1.86 Mar/2026